Heart disease is the leading cause of death. A cardiologist takes 3 supplements to lower his risk.
He shared the supplements he personally takes for his cardiovascular health.
Studies show that omega-3, magnesium, and vitamin D are all good for the heart.
Supplements can boost longevity, reduce inflammation, and aid in strength training. They can also improve cardiovascular health, according to a heart transplant cardiologist.
Dr. Dmitry Yaranov, the director of the advanced heart failure program at Baptist Memorial Hospital in Memphis, told Business Insider that being a cardiologist makes him extra aware of cardiovascular disease, the leading cause of death in the US.
"I'm always very conscious about my diet," Yaranov said, and that includes supplements to support his heart health. At the same time, he said the list of supplements he takes is "not long," as he tries to focus on supplements that have more research behind them.
Supplements "support a healthy lifestyle, but they don't replace a healthy lifestyle," Yaranov said, emphasizing the importance of practicing heart-healthy habits like regular exercise and a balanced diet. "I think that a lot of times, my patients forget about that."
Omega-3 reduces the risk of blood clots
Of all the supplements he takes, Yaranov said that omega-3 has the most research backing its heart health benefits.
Found in foods like salmon, anchovies, soybeans, and walnuts, omega-3 helps support healthy blood cells, reducing the risk of blood clots. It also helps to lower triglyceride levels, a type of fat that can cause plaque buildup in the arteries and eventually lead to a stroke, heart attack, or heart disease.
"I know that for sure, I'm not getting enough fresh, fatty fish in my diet," Yaranov said, which is why he's been taking omega-3 supplements for years.
Magnesium glycinate improves sleep
Magnesium supports heart, bone, brain, and muscle health, controlling processes like blood pressure. It can naturally be found in foods like spinach and black beans, but up to 15% of Americans are magnesium-deficient.
Yaranov emphasized that he checks his magnesium levels every six months to a year through bloodwork, since "certain levels of magnesium are dangerous for the heart." Taking too much magnesium can lead to irregular heart rhythms and even cardiac arrest. He said cardiologists recommend keeping magnesium near 2.0-2.2 mg/dL, especially in patients with heart disease.
Getting his bloodwork done also helped him find the right type of magnesium for his body. Yaranov takes magnesium glycinate, which promotes better sleep than other forms of magnesium due to the presence of glycine, an amino acid with calming qualities. Prior to taking it, he tried magnesium oxide, citrate, and salts, but they either didn't improve his levels or upset his stomach.
That "eventually will feed into cardiovascular health," as poor sleep negatively impacts the heart, he said. He also works out five days a week and sweats a lot, which can deplete the body's magnesium levels.
Vitamin D may prevent heart disease
Vitamin D is associated with a lower risk of heart attack in adults over 60. While more research is needed on the exact benefits vitamin D has on the heart, many researchers and clinicians believe there's no harm in supplementing with vitamin D, especially when it has other proven perks like helping the body absorb calcium and boosting the immune system. (While it's technically possible to overdose on vitamin D, it usually happens when people take more than their recommended value of vitamin D supplements.)
Vitamin D can be found through sun exposure and foods like fatty fish and milk. Yaranov said he spends "a long time indoors," which can contribute to vitamin D deficiency. When he learned his levels were low, he added vitamin D to his list of daily supplements.
Read the original article on Business Insider
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Modern Flu Vaccines Provide Equal Protection for US Seniors
TOPLINE: During the 2022-2023 influenza season, an adjuvanted quadrivalent influenza vaccine (aQIV) and high-dose (HD) QIV showed comparable effectiveness at preventing test-confirmed influenza among US adults aged 65 years or older across all hospital settings. METHODOLOGY: Researchers conducted a retrospective study using the test-negative design to evaluate the effectiveness of the aQIV vs HD-QIV in preventing laboratory-confirmed influenza among US adults aged 65 years or older during the 2022-2023 influenza season. They analyzed data of 30,911 patients (mean age, 76.7 years) from a linked administrative claims database who had an acute respiratory or febrile illness, were tested for influenza within 7 days of diagnosis, and received either aQIV or HD-QIV. Patients who tested positive for influenza (n = 2361) were classified as cases, whereas those who tested negative (n = 28,550) were considered control individuals. The analysis was adjusted for demographic and clinical covariates, including insurance type, frailty index, healthcare utilization, comorbidities, and medical conditions associated with an increased risk for influenza complications. TAKEAWAY: Overall, 31.8% and 68.2% received the aQIV and HD-QIV, respectively, with comparable rates of test-positive influenza between groups during the observation period (7.2% and 7.9%, respectively). The relative vaccine effectiveness (rVE) of aQIV vs HD-QIV showed no significant difference across all settings (adjusted rVE, -2.5%; P = .631) and emergency department/inpatient settings (adjusted rVE, 0.0%; 95% CI, -15.9% to 13.7%). During the peak season (6 November to 24 December 2022), 13.6% of aQIV and 14.4% of HD-QIV recipients tested positive for influenza, and the rVE in the sensitivity analysis was consistent with that in the main analysis. IN PRACTICE: 'These findings align with current recommendations by ACIP [Advisory Committee on Immunization Practices] and other NITAGs [National Immunization Technical Advisory Groups] that support the use of adjuvanted and high-dose influenza vaccines in this age group,' the authors wrote. SOURCE: This study was led by Mahrukh Imran, CSL Seqirus, Kirkland, Quebec, Canada. It was published online on July 11, 2025, in International Journal of Infectious Diseases. LIMITATIONS: The observational study design introduced potential biases due to variability in the use of healthcare resources and heterogeneity inherent in the US healthcare system, which could not be fully accounted for. Vaccination was not randomized, and unmeasured confounding factors might have influenced the results. The limited sample size and data privacy constraints prevented a more detailed geographic analysis. Moreover, influenza testing was performed as part of routine care than according to preset screening criteria. DISCLOSURES: This study was supported by CSL Seqirus. Three authors reported being employees of CSL Seqirus and holding stock in CSL Limited. Three other authors reported being employees of Optum, which received funding from CSL Seqirus to support this work. One author reported receiving direct financial support from the study funders. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
an hour ago
- Medscape
Brain-Boosting Supplements: All Hype or Some Hope?
Media consumers are bombarded daily with aggressive, testimonial-driven ads for pricey supplements purported to sharpen memory, focus, and working brain function. Some even claim to stop or slow the development of dementia. Patients, especially older adults, may express interest in these supplements during clinic visits. Most claim to be 'clinically tested.' However, since the FDA exercises only limited regulatory control over these products, they are not held to the same purity, safety, and efficacy standards as are FDA-approved drugs. 'Manufacturers have a lot of leeway to market them as they want,' said Pieter Cohen, MD, director of the Supplement Research Program at the Cambridge Health Alliance in Somerville, Massachusetts, and an associate professor of medicine at Harvard Medical School in Boston. 'That's not to say they haven't been studied — there might be small studies posted online done in, say, 100 people in another country, for example.' Pieter Cohen, MD Cohen, therefore, does not generally recommend that his patients take them to improve brain health, 'although I do recommend supplements to patients who need them to treat medical conditions,' he told Medscape Medical News . Many contain dubious or unlisted ingredients, he noted. In a 2021 study of over-the-counter (OTC) cognitive enhancement supplements, Cohen and colleagues identified unapproved drugs (omberacetam, aniracetam, phenibut, vinpocetine, and picamilon) — as well as compounds not listed on the label and with unknown health effects. For those products with ingredient quantities provided on the labels, 75% of declared quantities were inaccurate. These OTC brain enhancers may feature, alone or in combination, nonpharmaceutical ingredients such as vitamins (including vitamin E), minerals like magnesium, omega-3 fatty acids, turmeric, and herbal compounds like ginseng, Ginkgo biloba , and coffee fruit extract. Some feature alleged boosters of brain performance that are less familiar, including alpha-GPC (L-alpha-glycerylphosphorylcholine), huperzine A, the Chinese mushroom lion's mane, L-carnitine, and the Ayurvedic medicine compound Bacopa monnieri . Some ingredients are more exotic. The memory enhancer Prevagen, for example, contains apoaequorin, a lab-made version of a protein found in the bioluminescent jellyfish Aequorea victoria . In 2024, the Federal Trade Commission and a federal district court in New York State ordered Prevagen's makers to stop their claims on the grounds they lacked reliable evidence. Jayne Zhang, MD The brain health supplements all have one thing in common, noted Jayne Zhang, MD, an attending neurologist specializing in cerebrovascular disease at Johns Hopkins School of Medicine in Baltimore — uncertain evidence of claimed efficacy. 'There is some modest support for a benefit from these products in people who already have nutritional deficiencies or mental degeneration, but there's not a lot of strong evidence from rigorous trials,' she told Medscape Medical News . Added Alejandra Sánchez López, MD, an assistant clinical professor of neurology and geriatric medicine at the Mary S. Easton Center for Alzheimer's Disease Research at the University of California, Los Angeles, 'Weak evidence of benefit usually comes from studies with small sample sizes and sponsored by the manufacturing company.' Alejandra Sánchez López, MD Like Cohen, Sánchez López recommends that her patients not take the brain supplements. 'They come with palpable GI [gastrointestinal] side effects such as nausea and diarrhea,' she said. Zhang is more open to patients' hopeful inquiries. 'I try not to be dismissive. Instead, I ask them what they're hoping a supplement will do for them, then I reveal what we know about them and talk about safety.' Zhang uses these encounters with OTC nootropics to talk about improving cognitive function in other ways: good nutrition, exercise, sleep, alcohol reduction, and social engagement, as well as proven medical therapies that mitigate cognition-impairing conditions such as depression, hyperglycemia, and hypertension. 'Patients need to understand there is no magic pill for brain health,' she said. The old-fashioned multivitamin tablet shows some promise, however. In a large National Institutes of Health-funded, placebo- and comparator-controlled randomized trial, Baker and colleagues found that older adults given a multivitamin had higher global cognition scores than those who did not take it. Specific effects on global cognition, episodic memory, and executive function were noted. The improvement was most pronounced in those with a history of cardiovascular disease. Safety Potential toxicity must be an issue with any loosely or unregulated OTC supplement, especially if taken over the long term. A content analysis of 12 cognitive supplements found the majority had at least one ingredient listed but not detected or, conversely, contained compounds detected but not reported on the label. And as noted, they can contain unapproved and potentially dangerous drugs. Drug interactions are another safety issue. Some dietary supplements can affect the pharmacokinetics of prescription drugs, altering their absorption, metabolism, or excretion and decreasing or increasing their potency. So, clinicians need to urge patients to be cautious, Sánchez López said. 'I always ask my patients to show me what supplements they're taking, and I go over the ingredient list.' A Dietetic Approach to Cognitive Health Emma Laing, PhD, RDN, a clinical professor and director of dietetics at the University of Georgia in Athens, Georgia, noted that a safer, proven alternative to commercial cognitive supplements can be found in the kitchen. 'While genetic predisposition, medical conditions, and environment are strongly linked to brain health, consuming a wide variety of nutrient-dense foods can improve cognitive health and reduce your risk for chronic disease,' she told Medscape Medical News . Emma Laing, PhD, RDN Minimally processed, nutrient-dense foods have been shown to support neurologic health, along with coffee and tea, Laing added. And even a small reduction in alcohol intake can improve cognitive function. Both the Mediterranean diet and the 'brain-healthy' MIND Diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) — a hybrid of the Mediterranean and DASH (Dietary Approaches to Stop Hypertension) regimens — have been well studied for their potential role in supporting cognitive function, memory, and alertness. Nootropics with cognitive potential are under ongoing evaluation, but until large scientific studies establish a positive effect of commercial brain health supplements on cognition, a healthy lifestyle may deliver more solid benefits to the brain.
Yahoo
2 hours ago
- Yahoo
AstraZeneca Profit, Revenue Lifted by Cancer Drugs
AstraZeneca Plc reported better-than-expected sales and rising profit for the second quarter, spurred by its stable of cancer medicines and growth in the US. Chief Executive Officer Pascal Soriot has turned the company into an oncology powerhouse, and increasing the company's presence in the U.S.. The company pledged $50 billion by 2030 in both production and research and development. Soriot told Bloomberg Businessweek Daily the company wants to work with states that work quickly and understand the pharmaceutical giant's vision.
